ストックスクリーナーアプリを入手
0.718
41.03%
-0.452
前日終値:
$1.17
開ける：
$0.69
24時間の取引高:
70,219
Relative Volume:
66.00
時価総額：
$N/A
収益：
-
当期純損益:
$-16.63M
株価収益率:
-1.6698
EPS:
-0.43
ネットキャッシュフロー:
$-21.84M
1週間 パフォーマンス:
-41.03%
1か月 パフォーマンス:
-43.90%
6か月 パフォーマンス:
-68.49%
1年 パフォーマンス:
-87.10%
1日の値動き範囲:
$0.66
$0.73
1週間の範囲:
$0.66
$0.73
52週間の値動き範囲:
$0.66
$0.73
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
BCLI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
0.718 | 0 | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-02-04 | アップグレード | Maxim Group | Hold → Buy |
| 2020-11-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2016-12-19 | 繰り返されました | Maxim Group | Buy |
| 2015-12-22 | 繰り返されました | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc (BCLI) 最新ニュース
What analysts say about Brainstorm Cell Therapeutics Inc. stockSuperior risk-adjusted returns - PrintWeekIndia
What drives Brainstorm Cell Therapeutics Inc. stock priceRapid capital growth - PrintWeekIndia
What risks could impact Brainstorm Cell Therapeutics Inc. stock performanceMarket-beating performance - jammulinksnews.com
Is Brainstorm Cell Therapeutics Inc. a good long term investmentFree Stock Selection - PrintWeekIndia
How Brainstorm Cell Therapeutics Inc. stock reacts to Fed policy changesAccelerated financial growth - jammulinksnews.com
BrainStorm Cell Therapeutics Downgraded to Hold by Maxim Group - AInvest
Maxim Group Downgrades Brainstorm Cell Therapeutics(BCLI.US) to Hold Rating, Raises Target Price to $6.6 - 富途牛牛
Brainstorm Cell Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - jammulinksnews.com
BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down - MSN
INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time' - Stocktwits
Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement - inkl
Brainstorm Cell Therapeutics Announces Nasdaq Delisting And Transition To Otcqb - TradingView
Brainstorm Cell Therapeutics Faces Nasdaq Delisting Notice - TipRanks
Brainstorm Cell Therapeutics to Delist From Nasdaq - MarketScreener
BrainStorm Cell Therapeutics shares fall 51.20% after-hours after Nasdaq delisting notification. - AInvest
BrainStorm Cell Therapeutics stock delisted from Nasdaq, trades on OTCQB - AInvest
BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB By Investing.com - Investing.com India
BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB - Investing.com
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB - WV News
BrainStorm Receives 3 Million NIS Grant from Israel's Office of the Chief Scientist - AOL.com
Why Brainstorm Cell Therapeutics Inc. stock attracts strong analyst attentionFree Deep Market Trend Analysis - Newser
What makes Brainstorm Cell Therapeutics Inc. stock price move sharplyFree Stock Trading Community - Newser
How Brainstorm Cell Therapeutics Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn By Investing.com - Investing.com South Africa
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data - BioSpace
BTCS, BrainStorm Cell, Moderna - TradingView
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness - The Malaysian Reserve
BrainStorm Cell Therapeutics: A Rare Disease Breakthrough on the Brink of Regulatory Approval - AInvest
NurOwn's Regulatory Crossroads: Why BrainStorm Cell Therapeutics (BCLI) Could Be Poised for a Turnaround - AInvest
FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn - Investing.com
BCLI: Citizen's Petition Filed Requesting the FDA Approve NurOwn - Smartkarma
ALS Community Files Citizens’ Petition asking FDA to Approve NurOwn Stem Cell Therapy - Asbury Park Press
Brainstorm Cell Therapeutics Inc (BCLI) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):